FibroBiologics (FBLG) Research & Development (2023 - 2026)
FibroBiologics (FBLG) posted quarterly Research & Development of $1.7 million for Q2 2026, down 18.77% year-over-year from $2.0 million in Q2 2025, and down 43.85% on a QoQ basis from $3.0 million in Q1 2026.
FibroBiologics (FBLG) Research & Development (2023 - 2026) Analysis & Trends
FibroBiologics has reported Research & Development for 4 years, with the latest figure at $1.7 million in Q2 2026.
- Research & Development for Q2 2026 came in at $1.7 million, down 18.77% year-over-year; the trailing twelve-month figure through Jun 2026 was $8.2 million (up 28.28% YoY), and the FY2025 annual result was $7.4 million, up 64.45% from the prior year.
- Research & Development eased to $1.7 million in Q2 2026, from $3.0 million in the prior quarter.
- Over five years, Research & Development peaked at $3.0 million in Q1 2026 and troughed at $478000.0 in Q1 2023.
- A 4-year average of $1.3 million and a median of $1.1 million in 2024 frame the typical range for Research & Development.
- The largest YoY upside for Research & Development was 129.93% in 2025 against a maximum downside of 41.22% in 2025.
- A 4-year view of Research & Development shows it stood at $773000.0 in 2023, then soared by 75.42% to $1.4 million in 2024, then sank by 41.22% to $797000.0 in 2025, then soared by 108.03% to $1.7 million in 2026.
- Per Business Quant data, the three most recent Research & Development figures were $1.7 million in Q2 2026, $3.0 million in Q1 2026, and $797000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | FibroBiologics | 8.15 Mn | 8.15 Mn | - | 1.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.66 Mn |
| Mar 31, 2026 | 2.95 Mn |
| Dec 31, 2025 | 797,000.00 |
| Sep 30, 2025 | 2.79 Mn |
| Jun 30, 2025 | 2.04 Mn |
| Mar 31, 2025 | 1.78 Mn |
| Dec 31, 2024 | 1.36 Mn |
| Sep 30, 2024 | 1.21 Mn |
| Jun 30, 2024 | 975,000.00 |
| Mar 31, 2024 | 960,000.00 |
| Dec 31, 2023 | 773,000.00 |
| Sep 30, 2023 | 571,000.00 |
| Jun 30, 2023 | 547,000.00 |
| Mar 31, 2023 | 478,000.00 |